NCT06129890 Neuromodulation in Patients With Neuropathic Pain and Depression.
| NCT ID | NCT06129890 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Condition | Neuropathic Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-04-26 |
| Primary Completion | 2028-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-04-26 with a primary completion date of 2028-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
High-frequency repetitive transcranial magnetic stimulation of the primary motor cortex has shown its effect on refractory neuropathic pain, and rTMS of the dorsolateral prefrontal cortex is commonly used for treatment-resistant depression. The treatment for patients suffering from neuropathic pain and depression, concomitantly, still needs to be studied, as there are some specificities in both symptoms and brain functional MRI.
Eligibility Criteria
Inclusion Criteria: * Central or peripheral neuropathic pain * Chronic pain (present for more than 6 months) with intensity greater than or equal to 4/10 on the numerical scale * Pain present on a daily or near-daily basis (at least 4 days a week) * Patient not completely relieved by recommended drug treatments for first- and second-line neuropathic pain * Stable analgesic treatment (no new treatment or dosage adjustment) for at least one month, and will not need to be modified for the duration of the study. * Patient with a depressive episode characterized according to DSM V criteria * Indication for motor cortex rTMS by a neurologist * Patient can be followed for the entire duration of the study * Patient having received informed consent to participate in the study, and having co-signed a consent form with the investigator * Member or beneficiary of a social security scheme Exclusion Criteria: * Industrial accident or litigation * Contraindication to rTMS or MRI (seismotherapy treatment since the previous month; epilepsy and/or history of epilepsy; history of head trauma; neurosurgical lesion; intracranial hypertension; intracerebral metal clip; piercing; pacemaker; insulin pump; metal prosthesis; pregnant or breast-feeding woman; claustrophobia) * Drug or psychoactive substance abuse * Neuropathic pain in the context of a progressive pathology (HIV, cancer, systemic disease disease) * Presence of other pain more severe than that justifying inclusion * Patient unable to understand informed consent * Patient unwilling or unable to stop treatments prohibited during the study * Patient participating in another research protocol involving a drug within the 30 days prior to inclusion * Patient deprived of liberty or under legal protection (guardianship, curatorship, safeguard of justice safeguard, family safeguard) * Minor patient
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06129890 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Neuropathic Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06129890 currently recruiting?
Yes, NCT06129890 is actively recruiting participants. Contact the research team at roland.peyron@univ-st-etienne.fr for enrollment information.
Where is the NCT06129890 trial being conducted?
This trial is being conducted at Saint-Etienne, France.
Who is sponsoring the NCT06129890 clinical trial?
NCT06129890 is sponsored by Centre Hospitalier Universitaire de Saint Etienne. The trial plans to enroll 60 participants.